Related references
Note: Only part of the references are listed.Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas
Michalis V. Karamouzis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt
Fumiyuki Yamasaki et al.
CANCER RESEARCH (2007)
Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells totreatment with gefitinib
Floriana Morgillo et al.
CLINICAL CANCER RESEARCH (2007)
Epidermal growth factor receptor biology in head and neck cancer
Shailaja Kalyankrishna et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody
Y Wang et al.
MOLECULAR CANCER THERAPEUTICS (2005)
A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity
D Lu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788
S Kim et al.
MOLECULAR CANCER THERAPEUTICS (2005)
AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma Xenografts in nude mice
YW Park et al.
CLINICAL CANCER RESEARCH (2005)
Predictions of skin cancer incidence in the Netherlands up to 2015
E de Vries et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871
BD Cohen et al.
CLINICAL CANCER RESEARCH (2005)
The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy
GS Warshamana-Greene et al.
CLINICAL CANCER RESEARCH (2005)
Mortality risk from squamous cell skin cancer
GL Clayman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts
L Goetsch et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells
A Camirand et al.
BREAST CANCER RESEARCH (2005)
Insulin-like growth factor ligands, receptors, and binding proteins in cancer
E Foulstone et al.
JOURNAL OF PATHOLOGY (2005)
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
CS Mitsiades et al.
CANCER CELL (2004)
In vivo antitumor activity of NVP-AEW541 -: A novel, potent, and selective inhibitor of the IGF-IR kinase
C García-Echeverría et al.
CANCER CELL (2004)
Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels
P Delafontaine et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis
JP Steinbach et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
The therapeutic potential of agents targeting the type I insulin-like growth factor receptor
H Zhang et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2004)
Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade
OG Yigitbasi et al.
CANCER RESEARCH (2004)
Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth
A Girnita et al.
CANCER RESEARCH (2004)
Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells
SI Chisalita et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2004)
Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor - The phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals
DL Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation
SM Thomas et al.
CANCER TREATMENT REVIEWS (2004)
The igf-1 receptor in cancer biology
R Baserga et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
The insulin-like growth factor system and cancer
D LeRoith et al.
CANCER LETTERS (2003)
Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas
V Poulaki et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas
CH Baker et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
YH Lu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Signalling pathways involved in antiproliferative effects of IGFBP-3: a review
RC Baxter
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY (2001)
Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition
JM Nelson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
The effects of insulin-like growth factors on tumorigenesis and neoplastic growth
HM Khandwala et al.
ENDOCRINE REVIEWS (2000)
Share Paper
